|
Search
Search through the thousands of lawsuits, complaints and recalls on our site.
 |
Case ID: 4758 | Drugs / Medical | 04/13/2006
A class action lawsuit recently filed charged that Fosamax, one of the most prescribed drugs to help increase bone density, actually does the reverse on the bone in the jaw-by destroying it. The lawsuit claims that its maker, Merck, was negligent in promoting its osteoporosis drug. According to the lawsuit, Fosamax is a defective product because it can cause osteonecrosis of the jaw, or a rotting of the jaw bone. The suit alleges that Merck concealed and continues to hide Fosamax's potentially dangerous side effects from patients and doctors.
Fosamax is Merck's second best-selling drug bringing in $3.2 billion in revenue. It is taken by nearly 10 million men and women. According to the lawsuit, Fosamax belongs to a category of drugs known as nitrogenous bisphosphonates. Some other drugs in the same category are used for chemotherapy and the lawsuit claims medical journals had been reporting a connection between those medicines and the jaw condition. The suit contends that since Fosamax is in the same class of drugs, Merck should have known its product could lead to such problems. The lawsuit further alleges that the U.S. Food and Drug Administration asked Merck to add a warning to Fosamax's label in August of 2004 and that it has yet to comply with that request. Merck claims that it received a request from the FDA to update the label with information about the condition in January 2005. It says that by July 2005 information regarding the problem was on the label. The lawsuit is open to anyone that suffered osteonecrosis, or death of the jaw bone after taking Fosamax. If you or a loved one suffered such a condition, click the above link and one of our attorneys will contact you. At Lawcash.com, it is our goal to keep you informed about important legal cases, class actions and settlements. Our lawyers offer free legal evaluations in tort cases, class actions, personal injury, and other lawsuits because we are dedicated to helping you resolve your legal complaints. Other Drugs / Medical Cases of Interest InterMune Inc., a biopharmaceutical company based out of California, has agreed to pay the government $36.9 million to resolve criminal charges and civil liabilities in connection with allegations of illegally promoting Actimmune for treatment of idiopathic pulmonary fibrosis (IPF). A class action has been filed against pharmaceutical company Biovail Corporation (NYSE: BVF) and certain of its officers and directors by stockholders who purchased the company's common stock between May 17, 2002, and October 30, 2003. The action claims that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. A class action has been filed against pharmaceutical company Gilead Sciences, Inc. (Nasdaq: GILD) and certain of its officers and directors by stockholders who purchased the company's common stock between July 14 and October 28, 2003. The action claims that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities. A class action has been filed against pharmaceutical company SmithKline Beecham Corporation on behalf of all persons who purchased the antidepressant Paxil or Paxil CR (paroxatine) for children under the age of 18 between November 19, 1998, and the present. The suit alleges that the company committed fraud by suppressing clinical study data that indicated Paxil was ineffective for children. Several class actions have been filed against global medical products and services company Baxter International, Inc., (NYSE:BAX) and certain of its officers and directors by stockholders who purchased the company's common stock between April 19, 2001, and July 21, 2004. Also included, are all those who acquired Baxter's shares through its acquisitions of Autros, Fusion Medical, ESI Lederle, Acambis, Alpha-1, Cook Pharmaceutical, and Icodextrin, and present and former employees who purchased stock through Baxter's Retirement Savings Plans. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities.
The issue of corporate health plan prescription contraceptive coverage is a hot-button item lately. The parties have apparently reached a settlement in a nationwide action filed against supermarket chain Albertson's, Inc. on behalf of female employees who allege that the store and its subsidiaries have discriminated against them by refusing to pay for their prescription contraceptives, in violation of their civil rights.
|
IT'S FREE
|
© 2000 - 2008 Copyright. All rights reserved nola3, llc.
